Cefiderocol for Infections Caused by Multidrug-Resistant Gram-Negative Bacteria.In 2019, the U.S. Food and Drug Administration approved cefiderocol, a new treatment option for individuals with complicated urinary tract infections.  Cefiderocol is a cephalosporin antibiotic indicated for use in adults 18 years or older who have minimal treatment options due to resistance for complicated urinary tract infections caused by Escherichia coli, Klebsiella pneumoniae, Proteus mirabilis, Pseudomonas aeruginosa, and Enterobacter cloacae complex.  The recommended dose of cefiderocol is 2 g intravenously every 8 hours infused over 3 hours.  Gastrointestinal symptoms such as diarrhea and constipation are the most common adverse events reported by individuals taking cefiderocol.
cefiderocol
Cefiderocol for Infections Caused by Multidrug-Resistant Gram-Negative Bacteria.In 2019, the U.S. Food and Drug Administration approved cefiderocol, a new treatment option for individuals with complicated urinary tract infections. 
U.S. Food and Drug Administration
Cefiderocol for Infections Caused by Multidrug-Resistant Gram-Negative Bacteria.In 2019, the U.S. Food and Drug Administration approved cefiderocol, a new treatment option for individuals with complicated urinary tract infections.  Cefiderocol is a cephalosporin antibiotic indicated for use in adults 18 years or older who have minimal treatment options due to resistance for complicated urinary tract infections caused by Escherichia coli, Klebsiella pneumoniae, Proteus mirabilis, Pseudomonas aeruginosa, and Enterobacter cloacae complex.  The recommended dose of cefiderocol is 2 g intravenously every 8 hours infused over 3 hours.  Gastrointestinal symptoms such as diarrhea and constipation are the most common adverse events reported by individuals taking cefiderocol.
cefiderocol
Cefiderocol for Infections Caused by Multidrug-Resistant Gram-Negative Bacteria.In 2019, the U.S. Food and Drug Administration approved cefiderocol, a new treatment option for individuals with complicated urinary tract infections.  Cefiderocol is a cephalosporin antibiotic indicated for use in adults 18 years or older who have minimal treatment options due to resistance for complicated urinary tract infections caused by Escherichia coli, Klebsiella pneumoniae, Proteus mirabilis, Pseudomonas aeruginosa, and Enterobacter cloacae complex.  The recommended dose of cefiderocol is 2 g intravenously every 8 hours infused over 3 hours.  Gastrointestinal symptoms such as diarrhea and constipation are the most common adverse events reported by individuals taking cefiderocol.
cefiderocol